Absci

GRCHealthcare

Creating Drugs at the Speed of Ai. Absci is the drug & target discovery company harnessing deep learning AI & synthetic biology to expand the therapeutic potential of proteins

2010
Founded
16y
Age
$319M
Total funding
Healthcare
Area

Funding timeline

Oct 2024
Post-IPO Secondary - Absci
Undisclosed
Feb 2024
Post-IPO Equity - Absci
$75M
Mar 2021
Venture Round - Absci
$125M
Feb 2021
Corporate Round - Absci
Undisclosed
Oct 2020
Series E - Absci
$70M
Jan 2020
Series D - Absci
$10M
Dec 2019
Debt Financing - Absci
$5M
Jan 2019
Series D - Absci
$10M
May 2018
Series C - Absci
$12M
Aug 2017
Series B - Absci
Undisclosed
Feb 2016
Series A - Absci
$5M